Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huCART-meso in Mesothelin Expressing Cancers
NCT03054298Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Apr 2017
- Primary completion
- Nov 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART-meso cells in lung adenocarcinoma, ovarian cancer, primary peritoneal carcinoma (PPC) and 3 more (7 cohorts), sponsored by University of Pennsylvania. Primary endpoint: Number of Participants With Treatment-related Adverse Events at 7 years. Started Apr 2017; status: completed.
02
Drugs
huCART-meso cells
03
Conditions
lung adenocarcinomaovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)pleural mesothelioma
Beyond the preview
Go deeper on NCT03054298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054298.